Carcinoma, Non-Small-Cell Lung × Plasma cell × Clear all
NCT04314401 2026-03-18

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Recruiting
1,600 enrolled
NCT07440290 2026-02-27

DETERMINE

Cancer Research UK

Phase 2/3 Not yet recruiting
30 enrolled
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT02431260 2019-06-14

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
69 enrolled 34 charts
NCT00896454 2018-10-17

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Amgen

Phase 2 Completed
33 enrolled 22 charts
NCT00445952 2018-02-01

Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant

European Organisation for Research and Treatment of Cancer - EORTC

Completed
304 enrolled
NCT00899496 2017-05-30

Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants

Wake Forest University Health Sciences

Completed
54 enrolled
NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

INSYS Therapeutics Inc

Phase 3 Completed
130 enrolled 9 charts
NCT00006019 2013-06-24

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
NCT00045006 2013-05-30

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Completed
NCT00049296 2010-06-11

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Case Comprehensive Cancer Center

Phase 1 Completed
26 enrolled